Company Analysis GlaxoSmithKline
1. Summary
Advantages
- Dividends (3.93%) are higher than the sector average (1.31%).
- Current debt level 28.76% is below 100% and has decreased over 5 years from 37.02%.
- The company's current efficiency (ROE=36.92%) is higher than the sector average (ROE=-80.86%)
Disadvantages
- Price (33.09 $) is higher than fair price (10.9 $)
- The stock's return over the last year (-12.26%) is lower than the sector average (-0.7555%).
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| GlaxoSmithKline | Healthcare | Index | |
|---|---|---|---|
| 7 days | 2.5% | 2.4% | -0.1% |
| 90 days | -8.7% | -4.9% | 6.5% |
| 1 year | -12.3% | -0.8% | 25% |
GSK vs Sector: GlaxoSmithKline has significantly underperformed the "Healthcare" sector by -11.51% over the past year.
GSK vs Market: GlaxoSmithKline has significantly underperformed the market by -37.23% over the past year.
Stable price: GSK is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: GSK with weekly volatility of -0.2358% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (33.09 $) is higher than the fair price (10.9 $).
Price is higher than fair: The current price (33.09 $) is 67.1% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (24.31) is lower than that of the sector as a whole (57.87).
P/E vs Market: The company's P/E (24.31) is lower than that of the market as a whole (47.68).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (9.36) is lower than that of the sector as a whole (9.39).
P/BV vs Market: The company's P/BV (9.36) is lower than that of the market as a whole (22.59).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (3.95) is lower than that of the sector as a whole (4.07).
P/S vs Market: The company's P/S indicator (3.95) is lower than that of the market as a whole (15.21).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (14.52) is lower than that of the sector as a whole (17.62).
EV/Ebitda vs Market: The company's EV/Ebitda (14.52) is lower than that of the market as a whole (24.31).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -2.86% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-2.86%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-66.62%).
5.4. ROE
ROE vs Sector: The company's ROE (36.92%) is higher than that of the sector as a whole (-80.86%).
ROE vs Market: The company's ROE (36.92%) is higher than that of the market as a whole (18.08%).
5.5. ROA
ROA vs Sector: The company's ROA (8.35%) is higher than that of the sector as a whole (6.71%).
ROA vs Market: The company's ROA (8.35%) is higher than that of the market as a whole (6.49%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (12.84%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (12.84%) is higher than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 3.93% is higher than the average for the sector '1.31%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 3.93% has been steadily paid over the past 7 years, DSI=0.79.
Weak dividend growth: The company's dividend yield 3.93% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (45.6%) are at a comfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
